In the final results of the CVD-REAL trial, it was found that SGLT2i pharmacotherapy was associated with a 39% relative reduction in the risk of hospitalization for heart failure in patients with T2DM and a 51% reduction in the risk of death from any cause compared with other drugs for type 2 diabetes (e.g., metformin, sulfonylurea, DPP-4i, or insulin) [41]. The gene discussed is INS; the disease is type 2 diabetes mellitus.